| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
*Department of Anesthesiology, University of Würzburg; and Department of Anesthesiology, University of Marburg, Germany
Address correspondence and reprint requests to Peter Kranke, MD, Department of Anesthesiology, University of Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany. Address e-mail to peter.kranke{at}mail.uni-wuerzburg.de
The role of scopolamine administered via transdermal therapeutic systems in the prevention of postoperative vomiting, nausea, and nausea and vomiting is unclear. We performed a systematic search for full reports of randomized comparisons of transdermal scopolamine with inactive control. Dichotomous data were extracted. In the meta-analysis, relative risks and numbers-needed-to-treat/harm were calculated with 95% confidence intervals (CI). In 23 trials, 979 patients received transdermal scopolamine, and 984 patients received placebo. Sensitivity analyses were performed using restricted data for truncated control event rates (40%–80%) and for large trials. With these data, the relative risks for postoperative vomiting (five reports), nausea (five reports), nausea and vomiting (eight reports), and rescue treatment (three reports) were 0.69 (95% CI, 0.58–0.82), 0.69 (95% CI, 0.54–0.87), 0.76 (95% CI, 0.66–0.88), and 0.68 (95% CI, 0.54–0.85), respectively. This means that of 100 patients who receive transdermal scopolamine, approximately 17 will not experience postoperative vomiting who would have done so had they all received a placebo. However, 18 of 100 patients will have visual disturbances, eight will report dry mouth, two will report dizziness, one will be classified as being agitated, and 1–13 patients who are prescribed transdermal scopolamine will not use it correctly. The timing of application does not alter efficacy.
IMPLICATIONS:Of 100 patients who receive transdermal scopolamine, approximately 17 will not vomit in the postoperative period who would have done so had they all received a placebo. However, 18 of 100 patients will have visual disturbances, and eight will report dry mouth. Incorrect use further limits its efficacy.
This article has been cited by other articles:
|
|
 |
|
  R. Kapoor, E. T. Hola, R. T. Adamson, and A. S. Mathis Comparison of two instruments for assessing risk of postoperative nausea and vomiting Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 448 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Gan, T. A. Meyer, C. C. Apfel, F. Chung, P. J. Davis, A. S. Habib, V. D. Hooper, A. L. Kovac, P. Kranke, P. Myles, et al. Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting Anesth. Analg., December 1, 2007; 105(6): 1615 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. White, J. Tang, D. Song, J. E. Coleman, R. H. Wender, B. Ogunnaike, A. Sloninsky, R. Kapu, M. Shah, and T. Webb Transdermal Scopolamine: An Alternative to Ondansetron and Droperidol for the Prevention of Postoperative and Postdischarge Emetic Symptoms Anesth. Analg., January 1, 2007; 104(1): 92 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Wilhelm, M. L Dehoorne-Smith, and P. B Kale-Pradhan Prevention of Postoperative Nausea and Vomiting Ann. Pharmacother., January 1, 2007; 41(1): 68 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. P. Shan, R. Hatzakorzian, T. Schricker, S. Backman, and A. Deschamps 26423 - HEART RATE VARIABILITY TO PREDICT POSTOPERATIVE NAUSEA AND VOMITING Can J Anesth, June 1, 2006; 53(suppl_1): 26423 - 26423. [Full Text] [PDF]
|
|
|
|
|
|
J. Golembiewski, E. Chernin, and T. Chopra Prevention and treatment of postoperative nausea and vomiting Am. J. Health Syst. Pharm., June 15, 2005; 62(12): 1247 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kranke, A. M. Morin, N. Roewer, and L. H. Eberhart Patients' Global Evaluation of Analgesia and Safety of Injected Parecoxib for Postoperative Pain: A Quantitative Systematic Review Anesth. Analg., September 1, 2004; 99(3): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Habib and T. J. Gan Evidence-based management of postoperative nausea and vomiting: a review: [Le traitement des nausees et des vomissements postoperatoires fonde sur des donnees probantes : une revue] Can J Anesth, April 1, 2004; 51(4): 326 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Gan, T. Meyer, C. C. Apfel, F. Chung, P. J. Davis, S. Eubanks, A. Kovac, B. K. Philip, D. I. Sessler, J. Temo, et al. Consensus Guidelines for Managing Postoperative Nausea and Vomiting Anesth. Analg., July 1, 2003; 97(1): 62 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Horlocker, M. D. Abel, J. M. Messick Jr, and D. R. Schroeder Small Risk of Serious Neurologic Complications Related to Lumbar Epidural Catheter Placement in Anesthetized Patients Anesth. Analg., June 1, 2003; 96(6): 1547 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Beattie Strategies to reduce postoperative nausea and vomiting: does metoclopramide have a role?/Reduction des nausees et vomissements postoperatoires : le metoclopramide y joue-t-il un role ? Can J Anesth, December 1, 2002; 49(10): 1009 - 1015. [Full Text] [PDF]
|
|
|
